Dasatinib
Description:
Dasatinib by LC-MS/MS
Clinical details:
Dasatinib (Sprycel, Bristol-Myers Squibb) is a second-generation tyrosine kinase inhibitor (TKI). It is used in the treatment of chronic myeloid leukaemia (CML) in patients who have primary resistance to imatinib, which may occur in 15-20 % of cases. Treatment failure has been attributed to poor adherence or inadequate dosage. Thus, monitoring plasma dasatinib may help in assessing adherence and in optimising treatment. A target range for plasma dasatinib during effective therapy has not been established as yet. However, in patients (N = 33) prescribed (median, range) 100 (50-150) mg/d dasatinib for CML the median (range) pre-dose plasma dasatinib concentration was 13 (2-143) µg/L.
Units:
μg/L
Department:
Location:
Sample type and Volume required:
2mL EDTA whole blood or 1 mL plasma or serum (pre-dose or ‘trough’ sample).
Turnaround time:
5 working days
Storage and transport:
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Contacts:
Toxicology Department at King's Hospital
020 3299 5881
kch-tr.toxicology@nhs.net
King's College Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
Laboratory:
PDF (81.6Kb)
Last updated: 03/10/2022
